Related Experiment Video
Updated: Aug 13, 2026
07:54
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma--necessitating multiple site analysis
M J Warzynski1, C E Soechtig, T J Maatman
1West Michigan Flow Cytometry Service, Blodgett Memorial Medical Center-Ferguson Site, Grand Rapids 49503, USA.
The Prostate
|December 1, 1995
Summary
Prostate cancer DNA ploidy analysis can be misleading due to tumor heterogeneity. Analyzing multiple malignant sites in prostatectomy tissue is crucial for accurate DNA ploidy assessment, as 40% of patients showed varied results.
Area of Science:
- Urology
- Oncology
- Molecular Pathology
Background:
- DNA ploidy analysis in prostate cancer correlates with clinical outcomes.
- Tumor heterogeneity is a potential reason for conflicting reports in DNA ploidy studies.
- Previous studies using punch biopsies suggested DNA heterogeneity in prostate cancer.
Purpose of the Study:
- To investigate DNA ploidy heterogeneity within individual prostatectomy specimens.
- To determine the frequency of DNA content variation across different malignant sites in the prostate.
- To assess the necessity of analyzing multiple tumor areas for accurate prostate cancer ploidy status.
Main Methods:
- Whole mount prostatectomy tissues from 75 patients were sectioned every 0.6 cm.
- Malignant areas and normal tissue were isolated, and nuclei extracted using the Hedley technique.
- DNA content was analyzed using flow cytometry (FACScan) with propidium iodide staining.
Main Results:
- Forty percent (30/75) of patients exhibited DNA heterogeneity across multiple sampled malignant sites.
- Analysis of 322 histograms revealed an average coefficient of variation (CV) of 4.4%.
- Even after excluding certain ploidy types, 16% of patients showed diploid versus aneuploid heterogeneity.
Conclusions:
- Significant DNA ploidy heterogeneity exists within individual prostate cancers.
- Analyzing multiple malignant sites is essential for accurate assessment of prostatic adenocarcinoma ploidy.
- Current methods may underestimate tumor heterogeneity if only single sites are analyzed.
